Insulin Resistance, Hemostatic Factors, and Hormone Interactions in Pre- And Perimenopausal Women: SWAN

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 10, 2003, Pages 4904-4910

  Sowers, Maryfran ^a   Derby, Carol ^b   Jannausch, Mary L ^a   Torrens, Javier I ^c   Pasternak, Richard ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BLOOD CLOTTING FACTOR 7; ESTRADIOL; FIBRINOGEN; FOLLITROPIN; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX HORMONE; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLIMACTERIUM; DIABETES MELLITUS; ETHNOLOGY; FEMALE; HEART DISEASE; HEMOSTASIS; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; LONGITUDINAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; CLIMACTERIC; DIABETES MELLITUS, TYPE 2; ESTRADIOL; FACTOR VII; FEMALE; FIBRINOGEN; FOLLICLE STIMULATING HORMONE; HEMOSTASIS; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREMENOPAUSE; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0242320383     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030350     Document Type: Article

References (35)

1. Hoffmeister HS, Jur M, Wendel HP, Heller W, Seipel L 1995 Coronary artery disease/myocardial infarction: alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 91:2520-2527
2. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B 1987 Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3-9
3. Tousoulis D, Bosinakou E, Tentolouris C, Apostolopoulos T, Copshari C, Kyriakides M, Toutouzas P 1996 t-Plasminogen activator and von Willebrand factor in patients with unstable angina. Int J Cardiol 54:89-92
4. Wiman B, Andersson T, Hallqvist J, Reuterwall C, deFaire AAU 2000 Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEP) Study. Arterioscler Thromb Vasc Biol 20:2019-2023
5. Gottsater A, Rendell M, Hulthen UL, Berntorp E, Mattiasson I 2001 Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 249:237-246
6. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH 1995 Association between increased estrogen status and increased fibrinolytic potential in the Framingham-Offspring Study. Circulation 91:1952-1958
7. Scarabin PY, Allhencgelas M, Plubureau G, Taisne P, Agher R, Aiach M 1997 Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 17:3071-3078
8. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk In Communities Study Investigators. N Engl J Med 328:1069-1075
9. Estelles A, Cano A, Falco C, Espana F, Gilabert J, Grancha S, Aznar J 1999 Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause-influence of hormone replacement therapy. Thromb Haem 81:104-110
10. Ferreira AC, Montes MB, Franceschini SA, Toloi MR 2001 Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women. Int J Fertil Womens Med 46:265-270
11. Eliasson M, Asplund K, Evrin PE, Lindahl B, Lundblad D 1994 Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 43:1579-1586
12. Velazques EM, Mendoza SG, Wang P, Glueck CJ 1997 Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46:454-457
13. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L 1999 Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48:511-519
14. Sowers MF, Crawford S, Sternfeld B, Morgenstein D, Gold E, Greendale G, Evans D, Neer R, Matthews K, Sherman S, Lo A, Weiss G, Kelsey J 2000 SWAN: a multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition. In: Wren J, Lobo RA, Kelsey J, Marcus R, eds. Menopause: biology and pathobiology. New York: Academic Press; 175-188
15. Myers GL, Cooper GR, Winn CL, Smith SJ 1989 The Centers for Disease Control-National Heart, Lung and Blood Institute lipid standardization program. An approach to accurate and precise lipid measurements. Clin Lab Med 9:105-135
16. Haffner SM 1997 Progress in population analyses of the insulin resistance syndrome. Ann N Y Acad Sci 827:1-12
17. Steiner P, Freidel J, Bremner W, Stein EA 1981 Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem Biochem 19:850
18. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE 1994 Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 343:75-79
19. Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y 2002 Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 51:471-476
20. Duan N 1983 Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 78:605-661
21. Nestler JE 1993 Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 76:273-274
22. Nestler JE, Powers LLP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blanckard WG 1991 A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese with polycystic ovary syndrome. J Clin Endocrinol Metab 72:83-89
23. Haffner SM 1996 Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45:233-237
24. Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP 1993 Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 77:56-60
25. Loukovaara M, Carson M, Adlercreutz H 1995 Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. J Clin Endocrinol Metab 80:160-164
26. Plymate SR, Matej LA, Jones RE, Friedl KE 1988 Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460-464
27. Juhan-Vague I, Roui C, Alessi MC, Ardissone JP, Heim M, Vague P 1989 Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haem 61:370-373
28. Stoney RM, O'Dea K, Herbert KE, Dragicevic G, Giles GG, Cumpstom GN, Best JD 2001 Insulin resistance as a major determinant of increased coronary heart disease risk in postmenopausal women with type 2 diabetes mellitus. Diabet Med 18:476-482
29. Brandenburg SL, Reusch JE, Felder KK, Nelson-Wong E, Lindenfeld J, Manco-Johnson M, Regensteiner JG 2002 Impaired fibrinolysis in premenopausal women and age-matched men with type 2 diabetes mellitus: a pilot study. J Invest Med 50:110-115
30. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM 2002 Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137
31. Pugeat M, Crave JC, Elmidani M, Nicolas MH, Garscio-Cholet M, Leujene H, Dechaud H, Tourniarie J 1991 Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 40:841-849
32. Rosner W, Hrub DJ, Kahn MS, Nakhla AM, Romas NA 1999 Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol 69:481-485
33. Reed MJ, Dunkley SA, Singh A, Thomas BS, Haines AP, Cruickshank JK 1993 The role of free fatty acids in regulating the tissue availability and synthesis of sex steroids. Prostaglandins Leukot Essent Fatty Acids 48:111-116
34. Petra PH 1991 The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 40:735-753
35. Barbieri RL, Ryan KJ 1983 Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct patho physiologic features. Am J Obstet Gynecol 147:90-101